cv risk in t2d: adopting novel therapies into practice
Published 5 years ago • 28 plays • Length 4:19Download video MP4
Download video MP3
Similar videos
-
4:41
cv risk in t2d: role of sglt2 inhibition
-
8:24
cv risk reduction in t2d: establishing treatment goals
-
8:03
t2d and cv risk reduction: future management
-
35:39
acc decision pathway on cv risk reduction in t2d and ascvd
-
55:23
how chronic kidney disease in type 2 diabetes contributes to cardiovascular disease
-
15:31
false lows - when your sugar feels low, but isn't. diabetes pa explains
-
5:11
mcqs on cardiovascular disease
-
0:44
wegovy approved for cardiovascular risk reduction
-
5:07
type 2 diabetes and cardiovascular disease: risk factors
-
5:27
pathophysiology of type 2 diabetes & cardiovascular disease
-
3:56
therapies 'not used enough' in patients with type 2 diabetes and cardiovascular risk
-
3:19
overview of cardiovascular disease in cad, t2dm
-
27:18
diabetologist’s perspective of diabetes and cardiovascular risk management in post-acs t2d patients
-
14:56
is diabetes a cardiovascular risk equivalent?
-
59:39
the role of diabetes technology for people with type 2 diabetes and impact on cvd risk management
-
1:13:38
approaches to reducing cvd risk in type 2 diabetes
-
1:05:26
ask the experts: type 2 diabetes and cvd risk
-
3:35
covid-19 and cardiovascular risk: a new study
-
8:15
glucose-lowering therapies for cv risk reduction in type 2 diabetes
-
0:38
the root cause of heart disease, cancer & diabetes 🤯
-
3:47
diabetes and cardiovascular health
-
58:27
the role of sglt inhibitors in managing cvd risk in type 2 diabetes - webinar recording